Intelligence / TB-500

TB-500

Prescription Only
Tissue Repair
Schedule
S4
Prescription Only
Enforcement
Monitoring
Medium Risk
Providers
8
Access: Limited
Key Facts
Schedule 4 - Prescription Only
Synthetic Thymosin Beta-4 fragment
8 identified Australian providers
Some pharmacies have discontinued
Grey market availability remains high

Overview

TB-500 is a synthetic version of a naturally occurring 43-amino acid peptide (Thymosin Beta-4). Prescription availability is more limited than BPC-157, with some compounding pharmacies discontinuing it. Grey market supply remains readily available.

Australian Scheduling

Schedule 4 (Prescription Only). Currently under monitoring by the TGA. Some compounding pharmacies have discontinued TB-500, potentially signalling increased regulatory caution.

Access Pathway

Available through select telehealth providers and compounding pharmacies, but with fewer options than other tissue repair peptides. 8 identified providers. The limited prescription supply has driven demand toward the grey market.

Regulatory Notice

For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.

News & Updates15 items
Understanding the effects of ciprofloxacin on corneal epithelial cells: a study using electric cell-substrate impedance sensing (ECIS) technology
Exp Eye Res10 July 2026
Effects of Supplementation in Masters Athletes and Older Adults: A Narrative Review
Curr Sports Med Rep1 July 2026
Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function.
Investigative ophthalmology & visual science12 June 2026
Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction trial posted on ClinicalTrials.gov
ClinicalTrials.gov14 May 2026
Can peptide injections help people recover from injuries? Here’s what you need to know
The Conversation7 May 2026
PEGylated thymosin β4 is a thiol-site-specific prodrug treating myocardial infarction in vivo
Bioengineering & translational medicine31 Mar 2026
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD (TBRIDGE-CV Phase 1/2)
ClinicalTrials.gov23 Mar 2026
Comparative Proteomic Analysis of the Secretome of Control and BRAF/MEK Inhibitor-Resistant Melanoma Cells.
Journal of proteome research25 Feb 2026
2026 Prohibited List
Sport Integrity Australia1 Jan 2026
Utilizing Thymosin Beta-4 for Anti-Aging Regenerative Therapies
PMC1 June 2021
The regenerative peptide thymosin beta4 accelerates dermal healing in preclinical models and patients
PubMed1 Oct 2012
Thymosin beta4: a multi-functional regenerative peptide
PubMed1 Nov 2011
Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers
ClinicalTrials.gov1 Jan 2009
Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development
PubMed1 Mar 2004
Thymosin beta4 accelerates wound healing
PubMed1 Sept 1999

Are You a Practitioner?

List your clinic for free and reach patients actively searching for legal peptide access in Australia.